Literature DB >> 32796069

Non-nucleoside Inhibitors of Zika Virus RNA-Dependent RNA Polymerase.

Aicha Gharbi-Ayachi1,2, Sridhar Santhanakrishnan1,2, Yee Hwa Wong1,2, Kitti W K Chan3, Siok Thing Tan1,2, Roderick W Bates4, Subhash G Vasudevan3,5,6, Abbas El Sahili7,2, Julien Lescar7,2.   

Abstract

Zika virus (ZIKV) remains a potentially significant public health concern because it can cause teratogenic effects, such as microcephaly in newborns and neurological disease, like Guillain-Barré syndrome. Together with efforts to develop a vaccine, the discovery of antiviral molecules is important to control ZIKV infections and to prevent its most severe symptoms. Here, we report the development of small nonnucleoside inhibitors (NNIs) of ZIKV RNA-dependent RNA polymerase (RdRp) activity. These NNIs target an allosteric pocket (N pocket) located next to a putative hinge region between the thumb and the palm subdomains that was originally described for dengue virus (DENV) RdRp. We first tested the activity of DENV RdRp N-pocket inhibitors against ZIKV RdRp, introduced chemical modifications into these molecules, and assessed their potency using both enzymatic and cell-based assays. The most potent compound had a 50% inhibitory concentration value of 7.3 μM and inhibited ZIKV replication in a cell-based assay with a 50% effective concentration value of 24.3 μM. Importantly, we report four high-resolution crystal structures detailing how these NNIs insert into the N pocket of ZIKV RdRp. Our observations point to subtle differences in the size, shape, chemical environment, and hydration of the N pocket from ZIKV RdRp from those of the N pocket from DENV RdRp that are crucial for the design of improved antiviral inhibitors with activity against ZIKV.IMPORTANCE Zika virus belongs to the Flavivirus genus, which comprises several important human pathogens. There is currently neither an approved vaccine nor antiviral drugs available to prevent infection by ZIKV. The nonstructural protein 5 (NS5) polymerase, which is responsible for replicating the viral RNA genome, represents one of the most promising targets for antiviral drug development. Starting from compounds recently developed against dengue virus NS5, we designed and synthesized inhibitors targeting Zika virus NS5. We show that these novel compounds inhibit viral replication by targeting the polymerase activity. High-resolution X-ray crystallographic structures of protein-inhibitor complexes demonstrated specific binding to an allosteric site within the polymerase, called the N pocket. This work paves the way for the future structure-based design of potent compounds specifically targeting ZIKV RNA polymerase activity.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  RNA polymerases; Zika virus; nonstructural protein 5; polymerase inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32796069      PMCID: PMC7565630          DOI: 10.1128/JVI.00794-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Zika virus in Brazil and macular atrophy in a child with microcephaly.

Authors:  Camila V Ventura; Mauricio Maia; Vasco Bravo-Filho; Adriana L Góis; Rubens Belfort
Journal:  Lancet       Date:  2016-01-08       Impact factor: 79.321

2.  A fluorescence-based alkaline phosphatase-coupled polymerase assay for identification of inhibitors of dengue virus RNA-dependent RNA polymerase.

Authors:  Pornwaratt Niyomrattanakit; Siti Nurdiana Abas; Chin Chin Lim; David Beer; Pei-Yong Shi; Yen-Liang Chen
Journal:  J Biomol Screen       Date:  2011-01-10

Review 3.  The dengue virus NS5 protein as a target for drug discovery.

Authors:  Siew Pheng Lim; Christian G Noble; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2015-04-24       Impact factor: 5.970

Review 4.  A structural view of the RNA-dependent RNA polymerases from the Flavivirus genus.

Authors:  Guoliang Lu; Peng Gong
Journal:  Virus Res       Date:  2017-01-25       Impact factor: 3.303

Review 5.  Ten years of dengue drug discovery: progress and prospects.

Authors:  Siew Pheng Lim; Qing-Yin Wang; Christian G Noble; Yen-Liang Chen; Hongping Dong; Bin Zou; Fumiaki Yokokawa; Shahul Nilar; Paul Smith; David Beer; Julien Lescar; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2013-09-27       Impact factor: 5.970

6.  Zika virus NS5 protein potential inhibitors: an enhanced in silico approach in drug discovery.

Authors:  Pritika Ramharack; Mahmoud E S Soliman
Journal:  J Biomol Struct Dyn       Date:  2017-04-17

7.  The crystal structure of Zika virus NS5 reveals conserved drug targets.

Authors:  Wenqian Duan; Hao Song; Haiyuan Wang; Yan Chai; Chao Su; Jianxun Qi; Yi Shi; George F Gao
Journal:  EMBO J       Date:  2017-03-02       Impact factor: 11.598

8.  Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013.

Authors:  E Oehler; L Watrin; P Larre; I Leparc-Goffart; S Lastere; F Valour; L Baudouin; Hp Mallet; D Musso; F Ghawche
Journal:  Euro Surveill       Date:  2014-03-06

Review 9.  Dengue Virus Non-Structural Protein 5.

Authors:  Abbas El Sahili; Julien Lescar
Journal:  Viruses       Date:  2017-04-24       Impact factor: 5.048

10.  Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling.

Authors:  Siew Pheng Lim; Christian Guy Noble; Cheah Chen Seh; Tingjin Sherryl Soh; Abbas El Sahili; Grace Kar Yarn Chan; Julien Lescar; Rishi Arora; Timothy Benson; Shahul Nilar; Ujjini Manjunatha; Kah Fei Wan; Hongping Dong; Xuping Xie; Pei-Yong Shi; Fumiaki Yokokawa
Journal:  PLoS Pathog       Date:  2016-08-08       Impact factor: 6.823

View more
  7 in total

Review 1.  A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika.

Authors:  Shobana Sundar; Shanmughavel Piramanayagam; Jeyakumar Natarajan
Journal:  Virus Genes       Date:  2022-04-08       Impact factor: 2.332

2.  Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp.

Authors:  Zhuang Wang; Yunzheng Yan; Qingsong Dai; Yijie Xu; Jiye Yin; Wei Li; Yuexiang Li; Xiaotong Yang; Xiaojia Guo; Miaomiao Liu; Xingjuan Chen; Ruiyuan Cao; Wu Zhong
Journal:  Viruses       Date:  2022-06-05       Impact factor: 5.818

3.  Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.

Authors:  Xiaoming Bai; Hongmin Sun; Shuo Wu; Yuhuan Li; Lifei Wang; Bin Hong
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 4.  Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge.

Authors:  Francesca Picarazzi; Ilaria Vicenti; Francesco Saladini; Maurizio Zazzi; Mattia Mori
Journal:  Molecules       Date:  2020-12-03       Impact factor: 4.411

5.  Discovery of Bispecific Lead Compounds from Azadirachta indica against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations.

Authors:  Sanjay Kumar; Sherif A El-Kafrawy; Shiv Bharadwaj; S S Maitra; Thamir A Alandijany; Arwa A Faizo; Aiah M Khateb; Vivek Dhar Dwivedi; Esam I Azhar
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

6.  Chemoinformatic Design and Profiling of Derivatives of Dasabuvir, Efavirenz, and Tipranavir as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase and Methyltransferase.

Authors:  Madeleine I Ezeh; Onyinyechi E Okonkwo; Innocent N Okpoli; Chima E Orji; Benjamin U Modozie; Augustine C Onyema; Fortunatus C Ezebuo
Journal:  ACS Omega       Date:  2022-09-06

7.  Amino Acid Substitutions in NS5 Contribute Differentially to Tembusu Virus Attenuation in Ducklings and Cell Cultures.

Authors:  Xue Sun; Mengxu Sun; Lijiao Zhang; Ziding Yu; Jinxin Li; Wanying Xie; Jingliang Su
Journal:  Viruses       Date:  2021-05-16       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.